These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18536096)

  • 1. Bare-metal versus drug-eluting coronary stents.
    Agostoni P; Vermeersch P
    N Engl J Med; 2008 Jun; 358(23):2516-7; author reply 2517-8. PubMed ID: 18536096
    [No Abstract]   [Full Text] [Related]  

  • 2. The editor's roundtable: bare-metal stents versus drug-eluting stents-indications and complications.
    Friedewald VE; Kastrati A; Roberts WC; Vetrovec GW; Windecker S
    Am J Cardiol; 2008 Jul; 102(1):32-9. PubMed ID: 18572032
    [No Abstract]   [Full Text] [Related]  

  • 3. Late stent thrombosis with drug-eluting stents: the price to pay to prevent restenosis?
    Kumbhani DJ; Bavry AA; Bhatt DL
    Indian Heart J; 2007; 59(2 Suppl B):B113-7. PubMed ID: 19153427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heightened awareness of the thrombosis potential of drug-eluting stents may save lives.
    From RP; Tretsven J; O'Sullivan C
    J Clin Anesth; 2008 Dec; 20(8):624-5; author reply 626. PubMed ID: 19100939
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial: bare metal stents versus drug-eluting stents for saphenous vein grafts-an interventionalist's dilemma!
    Satpathy R
    J Interv Cardiol; 2011 Apr; 24(2):181-3. PubMed ID: 21457327
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug-eluting stents--for all, for some or for none?--Editorial].
    Kocka V; Widimský P
    Vnitr Lek; 2007 Oct; 53(10):1033-4. PubMed ID: 18072425
    [No Abstract]   [Full Text] [Related]  

  • 7. The balance of risks and benefits of drug-eluting versus bare-metal stents.
    Pfisterer M; Brunner-La Rocca HP; Kaiser C
    J Am Coll Cardiol; 2008 Mar; 51(9):972; author reply 972-3. PubMed ID: 18308171
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting coronary stents--promise and uncertainty.
    Curfman GD; Morrissey S; Jarcho JA; Drazen JM
    N Engl J Med; 2007 Mar; 356(10):1059-60. PubMed ID: 17296828
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study.
    Burzotta F; Parma A; Pristipino C; Manzoli A; Belloni F; Sardella G; Rigattieri S; Danesi A; Mazzarotto P; Summaria F; Romagnoli E; Prati F; Trani C; Crea F
    Eur Heart J; 2008 Dec; 29(24):3011-21. PubMed ID: 18987096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SA experts comment on clopidogrel and aspirin (dual platelet therapy) use with bare metal and drug-eluting stents.
    Cardiovasc J Afr; 2008; 19(1):58. PubMed ID: 18320095
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-eluting stents: some bare facts.
    Eisenberg MJ
    Lancet; 2004 Oct 23-29; 364(9444):1466-7. PubMed ID: 15500872
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug-eluting stents is their future as bright as their past?
    Kastrati A; Schömig A
    J Am Coll Cardiol; 2007 Jul; 50(2):146-8. PubMed ID: 17616298
    [No Abstract]   [Full Text] [Related]  

  • 15. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of drug-eluting stents.
    Saia F; Marzocchi A; Branzi A
    Ther Adv Cardiovasc Dis; 2008 Feb; 2(1):43-52. PubMed ID: 19124407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program.
    Ryan J; Linde-Zwirble W; Engelhart L; Cooper L; Cohen DJ
    Circulation; 2009 Feb; 119(7):952-61. PubMed ID: 19204307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent late drug-eluting stent thrombosis upon discontinuation of antiplatelet therapy.
    Varghese I; Ummer A; Roesle M; Banerjee S; Brilakis ES
    Cardiovasc Revasc Med; 2008; 9(3):179-81. PubMed ID: 18606381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The patient with coronary stents and antiplatelet agents: what to do and how to deal?
    Bornemann H; Prüller F; Metzler H
    Eur J Anaesthesiol; 2010 May; 27(5):406-10. PubMed ID: 20009935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.